QuidelOrtho Plans to Sell Testing Unit for $1.5B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 49 minutes ago
0mins
Source: seekingalpha
- Sale Plan: QuidelOrtho is evaluating bids from private equity groups, including Advent International, aiming to sell its point-of-care testing unit at a $1.5 billion valuation, which is intended to alleviate its $3.8 billion debt burden.
- Financial Status: As of March 31, QuidelOrtho reported total liabilities of $3.8 billion, with $3.5 billion in long-term borrowings, primarily due to a $6 billion cash-and-stock acquisition of Ortho Clinical Diagnostics in 2022 that significantly increased its debt load.
- Revenue Decline: The testing unit experienced a revenue drop of approximately 13% year-over-year to $601.6 million last year, indicating weak market demand and challenges faced by the company in the rapidly evolving medical testing sector.
- Transaction Progress: Although the sale process has reached an advanced stage, there is no guarantee that QuidelOrtho will ultimately proceed with the divestment, reflecting uncertainty in the company's strategic adjustments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QDEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QDEL
Wall Street analysts forecast QDEL stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 13.520
Low
35.00
Averages
35.00
High
35.00
Current: 13.520
Low
35.00
Averages
35.00
High
35.00
About QDEL
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Optix and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
QuidelOrtho Plans to Sell Testing Unit for $1.5B
- Sale Plan: QuidelOrtho is evaluating bids from private equity groups, including Advent International, aiming to sell its point-of-care testing unit at a $1.5 billion valuation, which is intended to alleviate its $3.8 billion debt burden.
- Financial Status: As of March 31, QuidelOrtho reported total liabilities of $3.8 billion, with $3.5 billion in long-term borrowings, primarily due to a $6 billion cash-and-stock acquisition of Ortho Clinical Diagnostics in 2022 that significantly increased its debt load.
- Revenue Decline: The testing unit experienced a revenue drop of approximately 13% year-over-year to $601.6 million last year, indicating weak market demand and challenges faced by the company in the rapidly evolving medical testing sector.
- Transaction Progress: Although the sale process has reached an advanced stage, there is no guarantee that QuidelOrtho will ultimately proceed with the divestment, reflecting uncertainty in the company's strategic adjustments.
See More
QuidelOrtho Appoints New CFO Micah Young Effective July 2026
- Executive Transition: QuidelOrtho has appointed Micah Young as Chief Financial Officer, effective July 6, 2026, succeeding Joseph Busky, who will remain in an advisory role to ensure a smooth leadership transition.
- Background Insight: Young joins from Masimo, where he served as Executive Vice President and CFO, and his extensive financial management experience is expected to bring new perspectives and strategic direction to QuidelOrtho's future growth.
- Financial Outlook: QuidelOrtho forecasts revenue between $2.7 billion and $2.75 billion for 2026, while targeting free cash flow of $100 million to $120 million, despite facing pricing uncertainties in the Chinese market, indicating confidence in future growth.
- Performance Review: In its recent earnings report, QuidelOrtho reported a non-GAAP EPS of $0.04, missing expectations by $0.38, with revenue of $620 million falling short of projections by $39.17 million, reflecting challenges in market competition.
See More
QuidelOrtho Appoints New CFO Micah Young
- Executive Change: QuidelOrtho announced the appointment of Micah Young as Chief Financial Officer, effective July 6, succeeding Joseph Busky who resigned, indicating a strategic shift in the company's leadership.
- Background Credentials: Micah Young previously served as CFO and Executive Vice President at Masimo Corporation, bringing extensive financial management experience from senior roles at NuVasive and Zimmer Holdings, which is expected to provide a fresh financial perspective for QuidelOrtho.
- Market Reaction: Following the announcement, QuidelOrtho shares fell 3.31% in pre-market trading on Nasdaq to $11.96, reflecting market uncertainty regarding the executive transition.
- Strategic Implications: This appointment could influence QuidelOrtho's financial strategy and future direction, particularly in the context of intense competition in the medtech industry, as new financial leadership may drive innovation in financial management and resource allocation.
See More
QuidelOrtho Appoints New CFO Micah Young to Drive Financial Strategy
- New CFO Appointment: QuidelOrtho announced the appointment of Micah Young as Chief Financial Officer effective July 6, 2026, succeeding retiring CFO Joseph M. Busky, aiming to enhance the company's financial performance and cash flow through Young's extensive medical technology experience.
- Leadership Recognition: CEO Brian J. Blaser emphasized Young's leadership in business strategy, capital allocation, and investor relations, which will be crucial in executing the company's priorities for profitability and cash generation.
- Past Achievements: Young previously served as CFO at Masimo Corporation, where he successfully led strategic transformation and operational improvements, showcasing his deep expertise and financial discipline in the medical technology sector.
- Future Outlook: Young expressed eagerness to collaborate with QuidelOrtho's leadership team to strengthen operational discipline, support growth, and create sustainable value for shareholders, customers, and patients, reflecting his confidence in the company's future development.
See More
QuidelOrtho Appoints New CFO Micah Young
- New CFO Appointment: QuidelOrtho announced that Micah Young will take over as Chief Financial Officer on July 6, 2026, succeeding the retiring Joseph M. Busky, ensuring a smooth transition in financial leadership for the company.
- Extensive Industry Experience: Micah Young brings over 20 years of leadership experience in the medical technology sector, having served as CFO at Masimo Corporation where he successfully led strategic transformation and improved financial performance, which is expected to positively impact QuidelOrtho similarly.
- Strategic Execution Capability: QuidelOrtho CEO Brian J. Blaser emphasized that Micah's leadership will aid in enhancing profitability, strengthening cash flow, and creating long-term shareholder value, indicating the company's focus on future growth.
- Transition Support: Joseph M. Busky will serve in an advisory role during the transition period, ensuring financial stability for the company during this critical transformation phase, reflecting QuidelOrtho's commitment to leadership changes and confidence in future developments.
See More
Three Russell 2000 Stocks to Avoid
- QuidelOrtho Underperformance: Formed from the 2022 merger of Quidel and Ortho Clinical Diagnostics, QuidelOrtho (market cap $960.8 million) has shown disappointing revenue performance over the past two years, indicating its product offerings are not resonating with customers, while its free cash flow margin has shrunk by 23 percentage points over five years, suggesting increased capital consumption to remain competitive.
- AMN Healthcare Demand Weakness: AMN Healthcare (market cap $1.19 billion) has seen a decline in travelers on assignment over the past two years, indicating soft demand, and its earnings per share have contracted by 7.1% annually, creating headwinds for stock prices as increasing competition erodes profitability.
- Nabors Industries Cost Risks: Operating one of the largest land-based drilling fleets globally, Nabors Industries (market cap $1.51 billion) faces challenges with a low gross margin of 39% and a poor free cash flow margin of 2.3% over the last five years, limiting its ability to invest in growth initiatives and indicating vulnerability due to high extraction costs and unfavorable asset economics.
- Small-Cap Investment Risks: Small-cap stocks in the Russell 2000 face greater challenges due to their instability and limited resources, making stock selection critical for investors, particularly for those companies showing underperformance, necessitating careful consideration of their long-term profitability and market competitiveness.
See More
QuidelOrtho Plans to Sell Testing Unit for $1.5B
- Sale Plan: QuidelOrtho is evaluating bids from private equity groups, including Advent International, aiming to sell its point-of-care testing unit at a $1.5 billion valuation, which is intended to alleviate its $3.8 billion debt burden.
- Financial Status: As of March 31, QuidelOrtho reported total liabilities of $3.8 billion, with $3.5 billion in long-term borrowings, primarily due to a $6 billion cash-and-stock acquisition of Ortho Clinical Diagnostics in 2022 that significantly increased its debt load.
- Revenue Decline: The testing unit experienced a revenue drop of approximately 13% year-over-year to $601.6 million last year, indicating weak market demand and challenges faced by the company in the rapidly evolving medical testing sector.
- Transaction Progress: Although the sale process has reached an advanced stage, there is no guarantee that QuidelOrtho will ultimately proceed with the divestment, reflecting uncertainty in the company's strategic adjustments.
See More
QuidelOrtho Appoints New CFO Micah Young Effective July 2026
- Executive Transition: QuidelOrtho has appointed Micah Young as Chief Financial Officer, effective July 6, 2026, succeeding Joseph Busky, who will remain in an advisory role to ensure a smooth leadership transition.
- Background Insight: Young joins from Masimo, where he served as Executive Vice President and CFO, and his extensive financial management experience is expected to bring new perspectives and strategic direction to QuidelOrtho's future growth.
- Financial Outlook: QuidelOrtho forecasts revenue between $2.7 billion and $2.75 billion for 2026, while targeting free cash flow of $100 million to $120 million, despite facing pricing uncertainties in the Chinese market, indicating confidence in future growth.
- Performance Review: In its recent earnings report, QuidelOrtho reported a non-GAAP EPS of $0.04, missing expectations by $0.38, with revenue of $620 million falling short of projections by $39.17 million, reflecting challenges in market competition.
See More
QuidelOrtho Appoints New CFO Micah Young
- Executive Change: QuidelOrtho announced the appointment of Micah Young as Chief Financial Officer, effective July 6, succeeding Joseph Busky who resigned, indicating a strategic shift in the company's leadership.
- Background Credentials: Micah Young previously served as CFO and Executive Vice President at Masimo Corporation, bringing extensive financial management experience from senior roles at NuVasive and Zimmer Holdings, which is expected to provide a fresh financial perspective for QuidelOrtho.
- Market Reaction: Following the announcement, QuidelOrtho shares fell 3.31% in pre-market trading on Nasdaq to $11.96, reflecting market uncertainty regarding the executive transition.
- Strategic Implications: This appointment could influence QuidelOrtho's financial strategy and future direction, particularly in the context of intense competition in the medtech industry, as new financial leadership may drive innovation in financial management and resource allocation.
See More
QuidelOrtho Appoints New CFO Micah Young to Drive Financial Strategy
- New CFO Appointment: QuidelOrtho announced the appointment of Micah Young as Chief Financial Officer effective July 6, 2026, succeeding retiring CFO Joseph M. Busky, aiming to enhance the company's financial performance and cash flow through Young's extensive medical technology experience.
- Leadership Recognition: CEO Brian J. Blaser emphasized Young's leadership in business strategy, capital allocation, and investor relations, which will be crucial in executing the company's priorities for profitability and cash generation.
- Past Achievements: Young previously served as CFO at Masimo Corporation, where he successfully led strategic transformation and operational improvements, showcasing his deep expertise and financial discipline in the medical technology sector.
- Future Outlook: Young expressed eagerness to collaborate with QuidelOrtho's leadership team to strengthen operational discipline, support growth, and create sustainable value for shareholders, customers, and patients, reflecting his confidence in the company's future development.
See More
QuidelOrtho Appoints New CFO Micah Young
- New CFO Appointment: QuidelOrtho announced that Micah Young will take over as Chief Financial Officer on July 6, 2026, succeeding the retiring Joseph M. Busky, ensuring a smooth transition in financial leadership for the company.
- Extensive Industry Experience: Micah Young brings over 20 years of leadership experience in the medical technology sector, having served as CFO at Masimo Corporation where he successfully led strategic transformation and improved financial performance, which is expected to positively impact QuidelOrtho similarly.
- Strategic Execution Capability: QuidelOrtho CEO Brian J. Blaser emphasized that Micah's leadership will aid in enhancing profitability, strengthening cash flow, and creating long-term shareholder value, indicating the company's focus on future growth.
- Transition Support: Joseph M. Busky will serve in an advisory role during the transition period, ensuring financial stability for the company during this critical transformation phase, reflecting QuidelOrtho's commitment to leadership changes and confidence in future developments.
See More
Three Russell 2000 Stocks to Avoid
- QuidelOrtho Underperformance: Formed from the 2022 merger of Quidel and Ortho Clinical Diagnostics, QuidelOrtho (market cap $960.8 million) has shown disappointing revenue performance over the past two years, indicating its product offerings are not resonating with customers, while its free cash flow margin has shrunk by 23 percentage points over five years, suggesting increased capital consumption to remain competitive.
- AMN Healthcare Demand Weakness: AMN Healthcare (market cap $1.19 billion) has seen a decline in travelers on assignment over the past two years, indicating soft demand, and its earnings per share have contracted by 7.1% annually, creating headwinds for stock prices as increasing competition erodes profitability.
- Nabors Industries Cost Risks: Operating one of the largest land-based drilling fleets globally, Nabors Industries (market cap $1.51 billion) faces challenges with a low gross margin of 39% and a poor free cash flow margin of 2.3% over the last five years, limiting its ability to invest in growth initiatives and indicating vulnerability due to high extraction costs and unfavorable asset economics.
- Small-Cap Investment Risks: Small-cap stocks in the Russell 2000 face greater challenges due to their instability and limited resources, making stock selection critical for investors, particularly for those companies showing underperformance, necessitating careful consideration of their long-term profitability and market competitiveness.
See More
